850649-62-6

• 常用中文名：阿格列汀苯甲酸盐
• 常用英文名：Alogliptin benzoate
• CAS号：850649-62-6
• 分子式：C₂₅H₂₇N₅O₄
• 分子量：461.513
• 相关类别： 医药中间体 原料药中间体
• 发布时间：2018-08-27 20:20:51
• 更新时间：2024-01-02 15:59:58
• Alogliptin benzoate(SYR 322)是高活性DPP-4抑制剂,IC50<10 nM,比对DPP-8和DPP-9的抑制性高10000倍。

名称

• 中文名: 2-[[6-[(3R)-3-氨基-1-哌啶基]-3,4-二氢-3-甲基-2,4-二氧代-1(2H)-嘧啶基]甲基]苯甲腈苯甲酸盐
• 英文名: alogliptin benzoate
• 中文别名: 苯甲酸阿格利汀; 苯甲酸阿格列汀; 阿格列汀苯甲酸盐; 苯甲酸盐阿格列汀
• 英文别名: Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-, benzoate (1:1); 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile,benzoic acid; SYR 322; Vipidia (TN); Alogliptin (Benzoate); Alogliptin benzoate; 2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzonitrile benzoate (1:1); 2-({6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile benzoate (1:1); alogliptin monobenzoate; Nesina; 2-[6-[3(R)-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]benzonitrile benzoate

物化性质

• 沸点: 671.2ºC at 760 mmHg
• 分子式: C₂₅H₂₇N₅O₄
• 分子量: 461.513
• 闪点: 359.7ºC
• 精确质量: 461.206299
• PSA: 134.35000
• LogP: 2.54458
• 外观性状: 白色-黄色 粉末
• 储存条件: 室温

生物活性

• 描述: Alogliptin benzoate(SYR 322)是高活性DPP-4抑制剂,IC50<10 nM,比对DPP-8和DPP-9的抑制性高10000倍。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> 二肽基肽酶
  研究领域 >> 代谢疾病
• 参考文献:

  [1]. Rendell M, et al. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012 Mar;13(4):553-63.

  [2]. Radha Andukuri, et al. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes. 2009; 2: 117-126.

  [3]. Takeuchi K, et al. Pharmacological and clinical profile of alogliptin benzoate (NESINA?).Nihon Yakurigaku Zasshi. 2011 Jan;137(1):43-50.

  [4]. Moritoh Y, et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.Eur J Pharmacol. 2008 Jul 7;588(2-3):325-32.